Company news

Seres Therapeutics, Inc. news in 2020

Seres Therapeutics, Inc.'s news releases, calls and decks from 2020, newest first.

View company

Seres Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Updates

November 8, 2020

Seres Therapeutics Announces Initiation of Phase 1b Trial of SER-301 for the Treatment of Ulcerative Colitis

November 5, 2020

Seres Therapeutics Expands Executive Team with Appointments of David S. Ege, Ph.D., as Chief Technology Officer and Jayne M. Gansler as Chief People Officer

October 21, 2020

Seres Therapeutics Announces U.S. Food and Drug Administration Correspondence Following Positive SER-109 Phase 3 Study Results

September 10, 2020

Seres Therapeutics, Inc. Announces Closing of Public Offerings of 12,075,000 Shares of Common Stock

August 16, 2020

Seres Therapeutics, Inc. Announces Pricing of Public Offering of 10,500,000 Shares of Common Stock

August 11, 2020

Seres Therapeutics, Inc. Announces Proposed Public Offering of Common Stock

August 10, 2020

Seres Therapeutics Announces Positive Topline Results from SER-109 Phase 3 ECOSPOR III Study in Recurrent C. difficile Infection

August 9, 2020

Seres Therapeutics Reports Second Quarter 2020 Financial Results and Provides Business Updates

July 27, 2020

Seres Therapeutics Appoints Terri Young, Ph.D., R.Ph., Experienced Commercial Leader, as Executive Vice President, Chief Commercial and Strategy Officer

June 21, 2020

Seres Therapeutics to Host Virtual SER-109 Focused Symposium on May 27, 2020, Ahead of Phase 3 ECOSPOR III Study Read-Out

May 17, 2020

Seres Therapeutics Reports First Quarter 2020 Financial Results and Provides Business Updates

May 6, 2020

Seres Therapeutics Appoints Lisa von Moltke, M.D., as Chief Medical Officer

April 5, 2020

Seres Therapeutics Announces Completion of Enrollment in SER-109 Phase 3 ECOSPOR III Study for Recurrent Clostridium difficile Infection and Provides Clinical Pipeline Updates

March 29, 2020

Seres Therapeutics Appoints Paul Biondi, Experienced Biopharmaceutical Strategy and Corporate Development Professional, to Its Board of Directors

March 22, 2020

Seres Therapeutics Issues Statement Regarding U.S. Food and Drug Administration’s March 12, 2020 Safety Alert Related to Use of Fecal Microbiota Transplantation

March 12, 2020

Seres Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Corporate Highlights

March 1, 2020

Calls in 2020

Decks in 2020